Treatment With Non-Replicative Ad5-CMV-mTNFα/mIL-2 and Continued ICI Improves the Anti-Tumor Response in Anti-PD-1 and Anti-PD-L1 Refractory MOC1 Tumors. This evidence concerns the gene CD274 and neoplasm.